NO327808B1 - 2H-1-benzopyranderivater, fremgangsmate ved fremstilling samt farmasoytiske sammensetninger derav - Google Patents
2H-1-benzopyranderivater, fremgangsmate ved fremstilling samt farmasoytiske sammensetninger derav Download PDFInfo
- Publication number
- NO327808B1 NO327808B1 NO20033318A NO20033318A NO327808B1 NO 327808 B1 NO327808 B1 NO 327808B1 NO 20033318 A NO20033318 A NO 20033318A NO 20033318 A NO20033318 A NO 20033318A NO 327808 B1 NO327808 B1 NO 327808B1
- Authority
- NO
- Norway
- Prior art keywords
- compound
- compounds
- bond
- phenyl
- solution
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 238000000034 method Methods 0.000 title abstract description 7
- 125000000850 2H-chromenyl group Chemical class O1C(C=CC2=CC=CC=C12)* 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 111
- 229940011871 estrogen Drugs 0.000 claims description 13
- 239000000262 estrogen Substances 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000004429 atom Chemical group 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims description 6
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 claims description 5
- 150000000463 2H-chromenes Chemical class 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- ZUDXUNPSRMREOJ-UHFFFAOYSA-N 3-(4-methoxyphenyl)-4-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]-2h-chromen-7-ol Chemical compound C1=CC(OC)=CC=C1C(COC1=CC(O)=CC=C11)=C1CC(C=C1)=CC=C1OCCN1CCCCC1 ZUDXUNPSRMREOJ-UHFFFAOYSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 25
- 230000007170 pathology Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 39
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 23
- 241000700159 Rattus Species 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 239000007787 solid Substances 0.000 description 17
- 235000019439 ethyl acetate Nutrition 0.000 description 16
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 15
- 229960004622 raloxifene Drugs 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000003208 petroleum Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 206010065687 Bone loss Diseases 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 239000011777 magnesium Substances 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 7
- 239000000556 agonist Substances 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 150000001562 benzopyrans Chemical class 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 6
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000004291 uterus Anatomy 0.000 description 6
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 229960001603 tamoxifen Drugs 0.000 description 5
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 235000016626 Agrimonia eupatoria Nutrition 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000196323 Marchantiophyta Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004705 lumbosacral region Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000008259 solid foam Substances 0.000 description 3
- VFLQQZCRHPIGJU-UHFFFAOYSA-N 1-(2-chloroethyl)piperidine;hydron;chloride Chemical compound Cl.ClCCN1CCCCC1 VFLQQZCRHPIGJU-UHFFFAOYSA-N 0.000 description 2
- UYQPSKUPEXAQRJ-UHFFFAOYSA-N 1-(chloromethyl)-4-phenylmethoxybenzene Chemical compound C1=CC(CCl)=CC=C1OCC1=CC=CC=C1 UYQPSKUPEXAQRJ-UHFFFAOYSA-N 0.000 description 2
- -1 2,2-dimethyl-propanoyl Chemical group 0.000 description 2
- SSIMHHUMYMHNID-UHFFFAOYSA-N 4-(chloromethyl)phenol Chemical compound OC1=CC=C(CCl)C=C1 SSIMHHUMYMHNID-UHFFFAOYSA-N 0.000 description 2
- WMKOZARWBMFKAS-UHFFFAOYSA-N 7-hydroxyisoflavone Chemical compound C=1C(O)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 WMKOZARWBMFKAS-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 2
- 102000044708 Eosinophil peroxidases Human genes 0.000 description 2
- 238000003747 Grignard reaction Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- XZEUAXYWNKYKPL-WDYNHAJCSA-N levormeloxifene Chemical compound C1([C@H]2[C@@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-WDYNHAJCSA-N 0.000 description 2
- 229950002728 levormeloxifene Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001836 utereotrophic effect Effects 0.000 description 2
- NIIVBDSTHWZTJC-UHFFFAOYSA-N (4-oxo-3-phenyl-2,3-dihydrochromen-7-yl) 2,2-dimethylpropanoate Chemical compound C1OC2=CC(OC(=O)C(C)(C)C)=CC=C2C(=O)C1C1=CC=CC=C1 NIIVBDSTHWZTJC-UHFFFAOYSA-N 0.000 description 1
- HBWSXWRFMUSIQF-UHFFFAOYSA-N (4-oxo-3-phenylchromen-7-yl) 2,2-dimethylpropanoate Chemical compound C=1C(OC(=O)C(C)(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 HBWSXWRFMUSIQF-UHFFFAOYSA-N 0.000 description 1
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical compound C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 125000003870 2-(1-piperidinyl)ethoxy group Chemical group [*]OC([H])([H])C([H])([H])N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- HQALDKFFRYFTKP-UHFFFAOYSA-N 2-[4-[4-(2-benzyl-1-benzothiophen-3-yl)phenyl]-2-bromo-6-(3-methoxyphenyl)phenoxy]acetic acid Chemical compound COC1=CC=CC(C=2C(=C(Br)C=C(C=2)C=2C=CC(=CC=2)C=2C3=CC=CC=C3SC=2CC=2C=CC=CC=2)OCC(O)=O)=C1 HQALDKFFRYFTKP-UHFFFAOYSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- QKFSKKROTLEPHN-UHFFFAOYSA-N 3-phenyl-4-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]-2h-chromen-7-ol Chemical compound C=1C=CC=CC=1C=1COC2=CC(O)=CC=C2C=1CC(C=C1)=CC=C1OCCN1CCCCC1 QKFSKKROTLEPHN-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- MKYQPGPNVYRMHI-UHFFFAOYSA-N Triphenylethylene Chemical group C=1C=CC=CC=1C=C(C=1C=CC=CC=1)C1=CC=CC=C1 MKYQPGPNVYRMHI-UHFFFAOYSA-N 0.000 description 1
- JJPSLYWPZOZHKQ-UHFFFAOYSA-N [3-(4-methoxyphenyl)-4-oxo-2,3-dihydrochromen-7-yl] 2,2-dimethylpropanoate Chemical compound C1=CC(OC)=CC=C1C1C(=O)C2=CC=C(OC(=O)C(C)(C)C)C=C2OC1 JJPSLYWPZOZHKQ-UHFFFAOYSA-N 0.000 description 1
- AJDUZBPZZMWNBB-UHFFFAOYSA-N [3-(4-methoxyphenyl)-4-oxochromen-7-yl] 2,2-dimethylpropanoate Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(OC(=O)C(C)(C)C)=CC=C2C1=O AJDUZBPZZMWNBB-UHFFFAOYSA-N 0.000 description 1
- WLLIDIRIQIVYDY-UHFFFAOYSA-N [4-hydroxy-3-(4-methoxyphenyl)-4-[(4-phenylmethoxyphenyl)methyl]-2,3-dihydrochromen-7-yl] 2,2-dimethylpropanoate Chemical compound C1=CC(OC)=CC=C1C1C(CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)(O)C2=CC=C(OC(=O)C(C)(C)C)C=C2OC1 WLLIDIRIQIVYDY-UHFFFAOYSA-N 0.000 description 1
- SVLCBAXPXIFJQF-UHFFFAOYSA-N [4-hydroxy-3-(4-methoxyphenyl)-4-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]-2,3-dihydrochromen-7-yl] 2,2-dimethylpropanoate Chemical compound C1=CC(OC)=CC=C1C1C(CC=2C=CC(OCCN3CCCCC3)=CC=2)(O)C2=CC=C(OC(=O)C(C)(C)C)C=C2OC1 SVLCBAXPXIFJQF-UHFFFAOYSA-N 0.000 description 1
- DVTHEVJDWHECGG-UHFFFAOYSA-N [4-hydroxy-4-[(4-hydroxyphenyl)methyl]-3-(4-methoxyphenyl)-2,3-dihydrochromen-7-yl] 2,2-dimethylpropanoate Chemical compound C1=CC(OC)=CC=C1C1C(CC=2C=CC(O)=CC=2)(O)C2=CC=C(OC(=O)C(C)(C)C)C=C2OC1 DVTHEVJDWHECGG-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 150000001348 alkyl chlorides Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000001395 anti-uterotrophic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 230000002444 effect on eosinophils Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 210000003049 pelvic bone Anatomy 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960003598 promazine Drugs 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01101521A EP1229036B1 (en) | 2001-01-24 | 2001-01-24 | 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof |
| EP01118682A EP1281710A1 (en) | 2001-08-03 | 2001-08-03 | 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof |
| PCT/EP2002/000567 WO2002059113A1 (en) | 2001-01-24 | 2002-01-21 | 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20033318D0 NO20033318D0 (no) | 2003-07-23 |
| NO20033318L NO20033318L (no) | 2003-09-24 |
| NO327808B1 true NO327808B1 (no) | 2009-09-28 |
Family
ID=26076450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20033318A NO327808B1 (no) | 2001-01-24 | 2003-07-23 | 2H-1-benzopyranderivater, fremgangsmate ved fremstilling samt farmasoytiske sammensetninger derav |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6951883B2 (ru) |
| EP (1) | EP1355906B1 (ru) |
| JP (1) | JP4332349B2 (ru) |
| CN (1) | CN1261431C (ru) |
| AT (1) | ATE286894T1 (ru) |
| AU (1) | AU2002237282B2 (ru) |
| BR (1) | BR0207066A (ru) |
| CA (1) | CA2435775A1 (ru) |
| CZ (1) | CZ20032014A3 (ru) |
| DE (1) | DE60202590T2 (ru) |
| DK (1) | DK1355906T3 (ru) |
| DZ (1) | DZ3459A1 (ru) |
| EA (1) | EA006158B1 (ru) |
| ES (1) | ES2236485T3 (ru) |
| HK (1) | HK1060558A1 (ru) |
| HU (1) | HUP0401018A3 (ru) |
| IL (2) | IL157065A0 (ru) |
| MA (1) | MA26982A1 (ru) |
| MX (1) | MXPA03006505A (ru) |
| NO (1) | NO327808B1 (ru) |
| NZ (1) | NZ527144A (ru) |
| PL (1) | PL365062A1 (ru) |
| PT (1) | PT1355906E (ru) |
| SI (1) | SI1355906T1 (ru) |
| SK (1) | SK287086B6 (ru) |
| TN (1) | TNSN03043A1 (ru) |
| WO (1) | WO2002059113A1 (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1809618B1 (en) * | 2004-09-21 | 2013-07-17 | Marshall Edwards, Inc. | Chroman derivatives, medicaments and use in therapy |
| US8080675B2 (en) | 2004-09-21 | 2011-12-20 | Marshall Edwards, Inc. | Chroman derivatives, medicaments and use in therapy |
| AU2005201855B2 (en) * | 2004-09-21 | 2012-03-29 | Marshall Edwards, Inc. | Chroman derived compounds and formulations thereof for use in therapy |
| ES2516067T3 (es) * | 2004-09-21 | 2014-10-30 | Mei Pharma, Inc. | Derivados de cromano sustituidos, medicamentos y utilización en terapia |
| JP4976649B2 (ja) * | 2004-09-21 | 2012-07-18 | マーシャル エドワーズ，インク． | 化合物 |
| US7601855B2 (en) | 2004-09-21 | 2009-10-13 | Novogen Research Pty Ltd | Substituted chroman derivatives, medicaments and use in therapy |
| CN101444499B (zh) * | 2007-11-26 | 2012-12-05 | 湘北威尔曼制药股份有限公司 | 一种化合物及其组合物的新用途 |
| EP2635121B1 (en) | 2010-11-01 | 2020-01-08 | MEI Pharma, Inc. | Isoflavonoid compounds and methods for the treatment of cancer |
| BR112015031903A8 (pt) | 2013-06-19 | 2019-12-31 | Seragon Pharmaceuticals Inc | composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto |
| HUE054998T2 (hu) | 2015-02-02 | 2021-10-28 | Mei Pharma Inc | Kombinációs terápiák emlõrák kezelésében való alkalmazásra |
| SG11201903908PA (en) * | 2016-11-17 | 2019-05-30 | Sanofi Sa | Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof |
| EP3681495A4 (en) * | 2017-09-15 | 2021-06-02 | Nyrada Pty Limited | TREATMENT OF EXZITOTOXICITY |
| CN112225716A (zh) * | 2020-10-30 | 2021-01-15 | 陕西嘉禾生物科技股份有限公司 | 一种鹰嘴豆牙素a的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3374245A (en) * | 1964-04-01 | 1968-03-19 | Ciba Geigy Corp | Unsaturated oxacycles |
| DE1518002C3 (de) * | 1965-01-02 | 1975-01-23 | Merck Patent Gmbh, 6100 Darmstadt | Isoflavane und Isoflavene und Verfahren zu Ihrer Herstellung sowie diese enthaltende Arzneimittel |
| US5280040A (en) * | 1993-03-11 | 1994-01-18 | Zymogenetics, Inc. | Methods for reducing bone loss using centchroman derivatives |
| JP2001502706A (ja) * | 1996-10-28 | 2001-02-27 | ノボ ノルディスク アクティーゼルスカブ | エストロゲン関連病あるいは症候群の予防または治療に有用な新規トランス―３，４クロマン誘導体 |
| US5985306A (en) * | 1996-10-28 | 1999-11-16 | Novo Nordisk A/S | (+)-enantiomers of cis-3,4-chroman derivatives useful in prevention or treatment of estrogen diseases or syndromes |
| ES2185054T3 (es) * | 1996-12-13 | 2003-04-16 | Chugai Pharmaceutical Co Ltd | Derivados de benzopirano. |
| KR20000001793A (ko) | 1998-06-13 | 2000-01-15 | 이경하 | 신규한 벤조피란 또는 티오벤조피란 유도체 |
| CA2356986A1 (en) * | 1998-12-30 | 2000-07-06 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
-
2002
- 2002-01-21 PL PL02365062A patent/PL365062A1/xx not_active IP Right Cessation
- 2002-01-21 US US10/466,118 patent/US6951883B2/en not_active Expired - Fee Related
- 2002-01-21 EP EP02703564A patent/EP1355906B1/en not_active Expired - Lifetime
- 2002-01-21 ES ES02703564T patent/ES2236485T3/es not_active Expired - Lifetime
- 2002-01-21 SK SK939-2003A patent/SK287086B6/sk not_active IP Right Cessation
- 2002-01-21 AT AT02703564T patent/ATE286894T1/de not_active IP Right Cessation
- 2002-01-21 DZ DZ023459A patent/DZ3459A1/fr active
- 2002-01-21 CN CNB02804066XA patent/CN1261431C/zh not_active Expired - Fee Related
- 2002-01-21 WO PCT/EP2002/000567 patent/WO2002059113A1/en active IP Right Grant
- 2002-01-21 BR BR0207066-9A patent/BR0207066A/pt not_active IP Right Cessation
- 2002-01-21 EA EA200300727A patent/EA006158B1/ru not_active IP Right Cessation
- 2002-01-21 DE DE60202590T patent/DE60202590T2/de not_active Expired - Lifetime
- 2002-01-21 JP JP2002559415A patent/JP4332349B2/ja not_active Expired - Fee Related
- 2002-01-21 SI SI200230096T patent/SI1355906T1/xx unknown
- 2002-01-21 HU HU0401018A patent/HUP0401018A3/hu unknown
- 2002-01-21 CZ CZ20032014A patent/CZ20032014A3/cs unknown
- 2002-01-21 MX MXPA03006505A patent/MXPA03006505A/es active IP Right Grant
- 2002-01-21 DK DK02703564T patent/DK1355906T3/da active
- 2002-01-21 AU AU2002237282A patent/AU2002237282B2/en not_active Ceased
- 2002-01-21 CA CA002435775A patent/CA2435775A1/en not_active Abandoned
- 2002-01-21 IL IL15706502A patent/IL157065A0/xx unknown
- 2002-01-21 NZ NZ527144A patent/NZ527144A/en unknown
- 2002-01-21 PT PT02703564T patent/PT1355906E/pt unknown
-
2003
- 2003-07-08 TN TNPCT/EP2002/000567A patent/TNSN03043A1/en unknown
- 2003-07-15 MA MA27236A patent/MA26982A1/fr unknown
- 2003-07-23 IL IL157065A patent/IL157065A/en not_active IP Right Cessation
- 2003-07-23 NO NO20033318A patent/NO327808B1/no not_active IP Right Cessation
-
2004
- 2004-04-26 HK HK04102904A patent/HK1060558A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1246814B1 (en) | Compounds and methods for modulation of estrogen receptors | |
| US6331562B1 (en) | Compounds and methods for modulation of estrogen receptors | |
| EP1140889B1 (en) | Compounds and methods for modulation of estrogen receptors | |
| US6291456B1 (en) | Compounds and methods for modulation of estrogen receptors | |
| NO327808B1 (no) | 2H-1-benzopyranderivater, fremgangsmate ved fremstilling samt farmasoytiske sammensetninger derav | |
| SK2862000A3 (en) | Substituted chroman derivatives | |
| AU2002237282A1 (en) | 2H-1-Benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof | |
| SK2872000A3 (en) | Substituted chroman derivatives | |
| US6043269A (en) | cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
| Gauthier et al. | Synthesis and structure–activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution | |
| EP1229036A1 (en) | 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof | |
| US5994390A (en) | Trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
| Gupta et al. | Rapid synthesis of 4-benzylidene and 4-[bis-(4-methoxyphenyl)-methylene-2-substituted phenyl-benzopyrans as potential selective estrogen receptor modulators (SERMs) using McMurry coupling reaction | |
| Rampa et al. | Homopterocarpanes as bridged triarylethylene analogues: synthesis and antagonistic effects in human MCF-7 breast cancer cells | |
| US20050282863A1 (en) | Novel-N substituted dihydrobenzothiepino, dihydrobenzoxepino and tetrahydro benzocyclohepta indoles as selective estrogen receptor modulators | |
| US6599921B2 (en) | Non-steroidal estrogen receptor ligands | |
| US7427686B2 (en) | (3R, 4R)-trans-3, 4-diarylchroman derivatives and a method for the prevention and/or treatment of estrogen dependent diseases | |
| WO2005035517A1 (en) | (3r, 4r)-trans-3,4-diarylchroman derivatives with estrogenic activity | |
| EP1281710A1 (en) | 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof | |
| US20020161007A1 (en) | Non-steroidal modulators of estrogen receptors | |
| AU9733501A (en) | Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |